Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

New TB booster Shows Promise

By R&D Editors | March 17, 2010

A booster shot appears to improve tuberculosis (TB) resistance in previously vaccinated adults, according to new research in South Africa.

The study has been published online ahead of print publication in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine.

“The world urgently needs new, better vaccines against TB,” said Willem Hanekom, M.B.Ch.B., associate professor and co-director, South African Tuberculosis Vaccine Initiative (SATVI). “It is important to test the safety of these vaccines in settings where TB is very common, such as South Africa.”

Every year 1.7 million people die from TB, according to the World Health Organization. This study is the first to report results from testing an adenovirus-35-based vaccine in humans. Adenovirus-35 is attractive to vaccine developers because fewer humans have been exposed to this strain of the virus, compared with many other adenoviruses, and the immunity from exposure is therefore less likely to interfere with the vaccine’s action.

The Aeras-402 vaccine, developed by Aeras Global Tuberculosis Foundation and Crucell, was made by weakening the virus in the lab, so that it can no longer replicate and cause disease. Parts of the TB bacterium that are important to stimulate the immune system (antigens) were then inserted into the virus.

“We showed that the vaccine was safe in healthy adults who have previously been vaccinated with the current TB vaccine, BCG,” said Dr. Hanekom. “Aeras-402 was able to stimulate the immune system in a manner thought to be important for protection against TB. This included activation of both CD4 and CD8 T cells. Potent activation of CD8 T cells by a new TB vaccine has not been demonstrated to date.”

Animal testing of AERAS-402 had showed promise, and the researchers had expected to see stimulation of CD4 cells, but were “pleasantly surprised” at how well CD8 T cells were also stimulated.

“We are completing a trial of Aeras-402 in babies, to make sure that the vaccine is safe and immunogenic in this population,” said Dr. Hanekom. “If all the studies go well, we will proceed with a Phase IIb study of Aeras-402 in up to 4,000 BCG-vaccinated babies, who will receive either the vaccine or a placebo in their first year of life. The results should indicate whether the vaccine may prevent TB disease. An effective booster vaccine would ultimately reduce the incidence of TB disease and, consequently, the spread of the TB pandemic.”

Date: March 17, 2010
Source: American Thoracic Society

Related Articles Read More >

Eli Lilly facility
9 R&D developments this week: Lilly builds major R&D center, Stratolaunch tests hypersonic craft, IBM chief urges AI R&D funding
professional photo of wooly mammoth in nature --ar 2:1 --personalize sq85hce --v 6.1 Job ID: 47185eaa-b213-4624-8bee-44f9e882feaa
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
3d rendered illustration of the anatomy of a cancer cell
Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE